Although high-dose methotrexate has been extensively studied in children with newly diagnosed acute lymphoblastic leukemia (ALL), there are fewer data in children with relapsed ALL, many of whom have been heavily pretreated and have subclinical kidney dysfunction. We characterized the pharmacokinetics of adaptively controlled methotrexate given as a 24-h infusion during consolidation therapy in 24 children with relapsed ALL. To achieve the target steady-state concentration of 65 M, dosage adjustments were required in 14 patients, with doses ranging from 2854 to 6700 mg/m 2 per course. The mean steady-state plasma concentration (Cp ss ) of 68.0 M was different (P = 0.025) than the predicted Cp ss (mean = 87.4 M; range 35.7-184 M) had no adjustment in dose been made. The coefficient of variation in Cp ss was reduced from 41% to 18% by individualizing doses. Predisposing factors that correlated with decreased methotrexate clearance were female sex (P = 0.03), age greater than 6 years (P = 0.01), and prior history of heavy amphotericin B treatment (Ͼ30 mg/kg) (P = 0.03), but no factor predicted low clearance as well as the measured initial methotrexate clearance during the infusion (P Ͻ 0.0001). There was no life-threatening toxicity with the regimen. We conclude that dosage individualization decreases interpatient variability and avoids potentially toxic methotrexate exposures in heavily pretreated ALL patients. Leukemia (2000) 14, 221-225.
Introduction
Acute lymphoblastic leukemia (ALL) in pediatrics is now a largely curable disease, with approximately 80% of children achieving 5 year survival on current, intensive protocols. 1 The most common adverse event in children achieving remission is hematologic relapse, with or without extramedullary involvement. 2 Retrieval regimens with intensive chemotherapy can achieve remission in 70-90% of patients; however, long-term event-free survival after relapse is not satisfactory. 3 One barrier to providing intense salvage chemotherapy to patients is decreased organ function secondary to previous, dose-intensive therapy.
Because of suspected decreased renal function in patients with relapsed ALL due to extensive pretreatment with nephrotoxic drugs, the St Jude Children's Research Hospital (SJCRH) R15 Study investigated the feasibility of targeting plasma concentrations of methotrexate to the average concentration achieved by patients receiving high-dose methotrexate (HDMTX) (5 g/m 2 ) with normal clearance. In this way, patients could have the cytotoxic benefits of receiving HDMTX while avoiding overtreatment and toxicities associated with prolonged exposure to high plasma concentrations of methotrexate.
In prior studies conducted at SJCRH, patients receiving HDMTX had an average clearance of 103 ml/min/m 2 . 4 This clearance would be predicted to achieve an average steadystate plasma concentration (Cp ss ) of 65.3 M when given 5 g/m 2 methotrexate as a 24 h infusion, based on prior reports. 5 In the current study, dosages were modified during the methotrexate infusion so that a Cp ss of 65 M ± 10 M at 24 h was achieved. . If the predicted Cp ss was Ͼ120 M, the infusion was held for 2 h, then restarted at a new rate using the above calculation.
Patients and methods

Patients and therapy
Pharmacokinetic parameters for a two-compartment model (volume of distribution for the central compartment (V c ), elimination rate constant (K el ), rate constants for methotrexate movement from the central to peripheral compartment (K cp ), and peripheral to central compartment (K pc ), were estimated using a Bayesian algorithm, as implemented in ADAPT (ADAPT II; Biomedical Simulations Resource, University of Southern California, Los Angeles, CA, USA). 6 The prior parameter estimates used for estimation were 10.9 l/m 2 , 0.58
, and 0.110 h −1 for V c , K e , K cp and K pc , respectively. Systemic clearance was estimated as V c · K el and AUC as dose divided by systemic clearance. Creatinine clearance was estimated from serum creatinine concentrations as outlined by Schwartz et al. 
Data analysis
Twenty-four patients were included in the data analysis. Five patients were excluded from the analysis due to incomplete documentation of dosages (n = 3), line contamination of plasma methotrexate concentration (n = 1), and failure to target methotrexate (n = 1). We analyzed whether clinical, laboratory, or pharmacokinetic parameters differed among patients who required a dosage increase, decrease, or no change using a Kruskal-Wallis, nonparametric ANOVA. We analyzed whether systemic clearance differed by patient characteristics (ie sex, race, urine pH during the infusion) using Mann-Whitney U tests, or whether clearance was correlated with other continuously distributed parameters (ie age, weight, body surface area, baseline serum creatinine, baseline blood urea nitrogen level, creatinine clearance, pharmacokinetic parameters, prior nephrotoxic drug exposure, prior courses of methotrexate, delayed methotrexate clearance after the infusion, toxicities from the current regimen) by Spearman Rank Correlation tests (Statistica for Windows; Statsoft, Tulsa, OK, USA).
Results
Characteristics of the 24 patients receiving targeted HDMTX during the consolidation phase of the SJCRH R15 protocol were as follows: 18 boys, six girls; 19 white, five nonwhite; median age 12.5 years (1. 5-22) . The median time from the end of the last antileukemic therapy to relapse was 180 days; one patient relapsed on therapy, 11 relapsed Ͻ6 months off therapy, and 12 patients relapsed Ͼ6 months off therapy.
Based on predicted Cp ss methotrexate concentrations, 12 patients required a dose decrease, 10 patients required no dose change, and two patients required a dose increase. Pharmacokinetic parameters categorized by the need for a dose change are listed in Table 1 . The initial clearance estimated from the 1 and 6 h concentrations was highly correlated with the final clearance based on 1, 6 and 23 h concentrations (P Ͻ 0.0001) (Figure 1) . Total dose given varied significantly between the three groups (P Ͻ 0.001), with a median overall dosage of 4519 mg/m 2 , but a wide range extending from 2854 mg/m 2 to 6700 mg/m 2 . The targeting strategy resulted in an average Cp ss at 23 h of 68.0 M, which was significantly different than that predicted had no dosage individualization been made (87.4 M), (P = 0.025). Thirty-eight percent of patients were predicted to have Cp ss greater than 90 M had no dosage change been made, whereas no patients had Cp ss greater than 90 M with individualization (P = 0.02). Moreover, the coefficient of variation in the Cp ss was only 18%, whereas the coefficients of variation in the measured 6 h concentration and the predicted Cp ss (if no dosage change was made), were 39% and 41%, respectively ( Figure 2) .
Other than the initial clearance based on the 1 and 6 h concentrations, the only predictors of low methotrexate clearance were female sex (P = 0.03), age greater than 6 years (P = 0.01), and history of heavy pretreatment (Ͼ30 mg/kg) with amphotericin B (P = 0.03) (Figure 3) . Thus, heavy amphotericin B pretreatment was associated with higher measured 6 h plasma concentrations (P = 0.03) and simulated 23 h concentrations (P = 0.02), but not with achieved 23 h concentrations (P = 0.89) because dosage was adjusted based on clearance. Although not statistically significant, the patient with the lowest methotrexate clearance was the only patient to receive amphotericin B concomitantly with the HDMTX. Subsequently, we have refrained from co-administration of amphotericin B with HDMTX.
Using this strategy of adaptive control of methotrexate, toxicities did not vary based on need for dose adjustment, total dose given, or methotrexate clearance. There was no difference in the proportion of courses followed by delayed methotrexate excretion among patients who did vs did not require a dosage change.
Grades 3-4 nonhematologic toxicity (as defined by the NCI Common Toxicity Criteria) with the regimen was acceptable including only five cases of gastrointestinal toxicities, nine cases of infection and one case of fever. These toxicities were unrelated to methotrexate AUC, 23 h concentration or 44 h concentration.
Discussion
This study investigated the effect of individualizing HDMTX doses for children with relapsed ALL. High plasma methotrexate concentrations have been associated with increased toxicity, delayed clearance of methotrexate, and delay of subsequent courses of chemotherapy. 8, 9 It is therefore important to maintain plasma concentrations within the putative cytotoxic range for leukemic blasts, but below those associated with significant toxicity. This study successfully targeted patients to concentrations within the range expected for a 5 g/m 2 dose of methotrexate, which has been associated with excellent outcome in newly diagnosed patients with ALL. 10 In 
Figure 1
Initial methotrexate clearance (as estimated from measured 1 and 6 h plasma concentrations as outlined in the text) vs final methotrexate clearance (as estimated from measured 1, 6 and 23 h levels as outlined in the text).
prior studies investigating the HDMTX regimen of 5 g/m 2 /24 h, expected plasma Cp ss have been 65 ± 33 M in previously untreated patients. 5 Therefore, we decided to target these children with relapsed ALL to 65 M. We found that in these patients with relapsed ALL, 11 of 24 patients required a dose decrease at 8 h. With dosage individualization, the mean observed Cp ss (68 M) was significantly closer to the target Cp ss (65 M), than would have been observed had no change in dose been made. With the targeting intervention, concentrations were in the range of Cp ss expected for a newly diagnosed ALL population, and there was an acceptable incidence of toxicity.
Although some clinical characteristics were predictive of low methotrexate clearance (ie female sex, age greater than 6 years of age, history of heavy amphotericin B pretreatment), the best predictor of high methotrexate Cp ss was the initial Leukemia methotrexate clearance during the infusion. In fact, with targeting, even patients with a prior history of high doses of amphotericin B achieved Cp ss that were within the range of patients who did not have that history. This suggests that targeting may be an important strategy to use for high-dose methotrexate in patients who have a significant history of previous exposure to nephrotoxic agents.
Clinical characteristics that lacked predictive value in assessing decreased clearance included baseline serum creatinine, BUN, calculated creatinine clearance, prior aminoglycoside usage, and prior courses of methotrexate. Thus, it was quite difficult to predict which patients would have a low clearance based on standard clinical parameters.
In this study, methotrexate clearance was lower in females than in males. Although we 11 and others have not reported sex differences in HDMTX clearance in other studies, it has been reported that RBC methotrexate polyglutamates were higher in females than in males. 12 Because boys have a worse prognosis than girls with ALL, 11, [13] [14] [15] [16] it is possible that higher exposure to methotrexate due to low clearance in girls could contribute to their better overall outcome. Assessing gender differences in methotrexate clearance for patients with relapsed ALL deserves closer study in additional trials.
Using this strategy of adaptive control, toxicity was not related to methotrexate exposure and was not life-threatening in any case. The rate of toxicity is similar to that previously seen with HDMTX/cytarabine regimens in front-line therapy trials for ALL patients. [17] [18] [19] [20] Because we have previously shown that delayed methotrexate excretion at approximately 44 h is more likely among patients with poor clearance during the 24 h infusion, it is possible that delayed excretion and therefore toxicity was minimized with this targeting strategy.
Methotrexate exposure is important for the prognosis of ALL patients. 4, [21] [22] [23] Anti-leukemic activity of methotrexate is linked to the duration of leukemic cell exposure and to the achieved plasma concentrations of methotrexate. 4, [24] [25] [26] [27] Because 
Figure 3
Methotrexate clearance tended to be higher in boys, patients р6 years of age, and in those who received a prior cumulative amphotericin B dose of Ͻ30 mg/kg. Horizontal lines indicate median, boxes indicate interquartile range, and whiskers indicate range.
patients with relapsed ALL have a more drug-resistant blast population, [25] [26] [27] higher concentrations or systemic exposure may be required in such patients.
Substantial data exist to support the practice of individualizing doses of drugs with narrow therapeutic indices (ie theophylline, aminoglycosides, vancomycin, etc), to avoid toxicity or underdosing. The ready availability of commercial assays for methotrexate makes such individualization possible, and in patients with heavy pretreatment and possible subclinical renal dysfunction, this may be a reasonable approach. The advantages of targeting methotrexate for these patients include prevention of over-treatment and subsequent toxicities and prevention of under-treatment and subsequent potential relapse.
